Novocure Ltd (NASDAQ:NVCR)’s share price fell 6.9% during trading on Tuesday . The company traded as low as $18.13 and last traded at $18.25. 1,107,000 shares were traded during mid-day trading, an increase of 30% from the average session volume of 853,570 shares. The stock had previously closed at $19.60.

A number of research firms recently commented on NVCR. Mizuho reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Novocure in a research note on Friday. Zacks Investment Research raised shares of Novocure from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Tuesday, October 31st. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Novocure in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Novocure in a research note on Monday, November 20th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Novocure currently has a consensus rating of “Buy” and an average target price of $21.00.

The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83.

Novocure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. Novocure had a negative net margin of 47.45% and a negative return on equity of 57.68%. The firm had revenue of $50.10 million during the quarter, compared to analyst estimates of $43.45 million. During the same quarter last year, the business posted ($0.39) EPS. The company’s revenue was up 130.9% on a year-over-year basis. equities research analysts anticipate that Novocure Ltd will post -0.65 EPS for the current year.

In other Novocure news, insider Yoram Palti sold 30,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $17.13, for a total value of $513,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Asaf Danziger sold 6,919 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $22.00, for a total transaction of $152,218.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 299,953 shares of company stock valued at $6,278,763. Insiders own 16.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in NVCR. Teachers Advisors LLC lifted its position in Novocure by 3.3% in the 1st quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock worth $800,000 after buying an additional 3,125 shares in the last quarter. Vanguard Group Inc. lifted its position in Novocure by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 3,047,940 shares of the medical equipment provider’s stock worth $24,688,000 after buying an additional 325,512 shares in the last quarter. Geode Capital Management LLC lifted its position in Novocure by 14.6% in the 1st quarter. Geode Capital Management LLC now owns 128,632 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 16,411 shares in the last quarter. Bank of America Corp DE lifted its position in Novocure by 61.7% in the 1st quarter. Bank of America Corp DE now owns 37,531 shares of the medical equipment provider’s stock worth $305,000 after buying an additional 14,321 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in Novocure by 1,919.7% in the 2nd quarter. Bank of Montreal Can now owns 7,069 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 6,719 shares in the last quarter. Institutional investors own 41.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/novocure-nvcr-trading-down-6-9/1746175.html.

About Novocure

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Receive News & Ratings for Novocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.